Jason Zell, DO
Disclosures: Nothing to disclose
Jason A

Jason A. Zell, DO, MPH

Associate Professor of Medicine

Program Director, Hematology/Oncology Fellowship Program

School of Medicine

University of California, Irvine

 

 

With a focus on treatment and prevention of colorectal cancer among other gastrointestinal malignancies, Dr. Zell has served as a translational oncology researcher and faculty member at the UC Irvine Chao Family Comprehensive Cancer Center (CFCCC) since 2007. Having board certifications in Medical Oncology, and Hematology by the American Board of Internal Medicine (ABIM), he maintains an active gastrointestinal oncology continuity clinic at the Cancer Center. Dr. Zell receives extramural research funding from the U.S. National Institutes of Health (NIH) to perform genetic epidemiology-based colorectal cancer research, and is principle investigator or co-investigator for several NIH-funded phase II cancer prevention clinical trials involving patients with gastrointestinal malignancies. His publication record includes >60 manuscripts and 3 book chapters, and has served on the Editorial Board for two cancer-related scientific journalsIn 2011 Dr. Zell was named co-Leader of the Cancer Center’s Colon Cancer Disease-Oriented Team (Colon Cancer DOT). This multidisciplinary team involves membership representing 4 Schools and 12 Departments at the University of California Irvine.  Nationally, within the National Cancer Institute (NCI)-supported Southwest Oncology Group (SWOG), Dr. Zell is the Cancer Control & Prevention Liaison to the Gastrointestinal Committee. He has been appointed to serve on 2 separate NCI-clinical trials steering committees (Cancer Prevention Steering Committee, and the Rectal/Anal Task Force of the Gastrointestinal Steering Committee). Additionally, he serves as national principle investigator for the NIH-supported phase III trial “S0820, a large multicenter trial aimed at reducing the risk of new tumor formation in colon cancer survivors.  The goal of this large colon cancer prevention trial is directly in line with Dr. Zell’s primary clinical and research focus:  decreasing the burden of colorectal cancer in society.

 

 

Brief 3-4 sentence version:

With a focus on treatment and prevention of colorectal cancer, Dr. Zell serves as a gastrointestinal (GI) medical oncologist and translational oncology researcher at the UC Irvine Chao Family Comprehensive Cancer Center (CFCCC). At UC Irvine, he is Program Director for the ACGME-accredited combined Hematology/Oncology fellowship training program.  Dr. Zell serves as principle investigator or co-investigator for several NIH-funded phase II GI cancer prevention clinical trials, and PI for a phase III colorectal cancer prevention trial conducted within the National Clinical Trials Network. Within the National Cancer Institute (NCI)-supported Southwest Oncology Group (SWOG), Dr. Zell is the Cancer Control & Prevention Liaison to the Gastrointestinal Committee. He serves as a Board Member of The Hope Foundation (the philanthropic arm of NCI-SWOG) and a Scientific Advisory Member for the Colon Cancer Alliance.  In 2017, Dr. Zell was appointed to serve on the NCI Gastrointestinal Committee’s Rectal/Anal Task Force and in 2019 he was appointed to serve as a member of the NCI Cancer Prevention Steering Committee.